Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
Keywords:
secukinumab, hidradenitis suppurativa, real-worldAbstract
Introduction: Treatment of hidradenitis suppurativa (HS) remains a challenge in clinical practice for dermatologists. Although the efficacy and safety of secukinumab (SEC) in the treatment of HS has been demonstrated in phase III studies, real-world data is limited.
Objectives: We conducted a retrospective multicenter study to evaluate the efficacy and safety of SEC treatment in HS patients in real-world settings.
Methods: Adult patients who were diagnosed with HS and used SEC for at least 3 months were included in the study.
Results: A total of 31 patients were included in the study; 14 of them (45.2%) were female. The mean age was 39.32 ± 10.26 years, and the mean disease duration was 11.77 ± 7.99 years. Nine (29%) patients were biologic-naive and 10 (32.3%) were adalimumab-naive. Disease severity was Hurley I in 7 patients (22.6%), Hurley II in 9 patients (29%), and Hurley III in 15 patients (48.4%). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 20 patients (64.5%) in the third month of treatment. SEC treatment was discontinued due to primary ineffectiveness in 9 (29%) patients, secondary ineffectiveness in 1 (3.2%) patient, adverse effects in 1 (3.2%) patient, and loss of follow-up in 1 (3.2%) patient. Paradoxical pyoderma gangrenosum was observed as an adverse effect in 1 patient that resolved after discontinuing SEC and starting infliximab.
Conclusion: SEC appears to be an effective and safe treatment option for HS, especially when used in the early and mild stages of the disease and in biologic-naive patients.
References
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. May 2020;82(5):1045-1058. DOI:10.1016/j.jaad.2019.08.090. PMID: 31604104.
Vossen A, van der Zee HH, Prens EP. Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Front Immunol. 2018;9:2965. DOI:10.3389/fimmu.2018.02965. PMID: 30619323. PMCID: PMC6302105.
Melnik BC, John SM, Chen W, Plewig G. T helper 17 cell/regulatory T‐cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities. British Journal of Dermatology. 2018;179(2):260-272. DOI:10.1111/bjd.16561
Matusiak Ł, Szczęch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. Apr 2017;76(4):670-675. DOI:10.1016/j.jaad.2016.10.042
Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. Mar 4 2023;401(10378):747-761. DOI:10.1016/s0140-6736(23)00022-3
Novartis Europharm Limited. Cosentyx® (secukinumab): summary of product characteristics. Accessed 2.4.2024, https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-medicine-overview_en.pdf
Novartis Europharm Limited. Cosentyx® (secukinumab) Biologic License Application (BLA): 761349. Accessed 2.4.2024, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s066,761349s004lbl.pdf
Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. Dec 2014;171(6):1434-42. DOI:10.1111/bjd.13270
Zouboulis CC, Passeron T, Pariser D, et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. Br J Dermatol. May 17 2024;190(6):836-845. DOI:10.1093/bjd/ljae098
Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. Sep 2019;181(3):609-611. DOI:10.1111/bjd.17822
Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. J Am Acad Dermatol. Jun 2020;82(6):1524-1526. DOI:10.1016/j.jaad.2020.02.005
Reguiaï Z, Fougerousse AC, Maccari F, Bécherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. Nov 2020;34(11):e750-e751. DOI:10.1111/jdv.16605
Melgosa Ramos FJ, García Ruiz R, Estébanez Corrales A, Mateu Puchades A. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients). J Eur Acad Dermatol Venereol. Apr 2023;37(4):e517-e519. DOI:10.1111/jdv.18685
Martora F, Marasca C, Cacciapuoti S, et al. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study. Clin Cosmet Investig Dermatol. 2024;17:159-166. DOI:10.2147/ccid.S449367
Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. Jul 2021;35(7):e441-e442. DOI:10.1111/jdv.17178
Roccuzzo G, Repetto F, Giordano S, et al. Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis. Exp Dermatol. Jul 2024;33(7):e15140. DOI:10.1111/exd.15140
Haselgruber S, Fernández-Crehuet-Serrano P, Fernández-Ballesteros MD, et al. Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study. Dermatol Ther (Heidelb). Jun 19 2024. DOI:10.1007/s13555-024-01209-w
Abu Rached N, Haven Y, Ocker L, Stockfleth E, Bechara FG. Real-world data about secukinumab in hidradenitis suppurativa: tobacco pack years an underestimated factor. Clin Exp Dermatol. Sep 21 2024. DOI:10.1093/ced/llae386
Marasca C, Megna M, Balato A, Balato N, Napolitano M, Fabbrocini G. Secukinumab and hidradenitis suppurativa: Friends or foes? JAAD Case Rep. Feb 2019;5(2):184-187. DOI:10.1016/j.jdcr.2018.12.002
Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. Jul 2018;179(1):182-185. DOI:10.1111/bjd.15769
Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab. Acta Derm Venereol. Jan 12 2018;98(1):151-152. DOI:10.2340/00015555-2794
Jørgensen AR, Yao Y, Thomsen SF. Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa. Case Rep Dermatol Med. 2018;2018:8685136. DOI:10.1155/2018/8685136
Villegas-Romero I, Collantes-Rodríguez C, Valenzuela-Ubiña S, Jiménez-Gallo D. Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab. Actas Dermosifiliogr (Engl Ed). Oct 2020;111(8):696-698. Hidradenitis supurativa moderada-grave tratada exitosamente con secukinumab. DOI:10.1016/j.ad.2019.07.007
Kridin K, Shani M, Schonmann Y, et al. Psoriasis and hidradenitis suppurativa: A large-scale population-based study. J Am Acad Dermatol. May 2023;88(5):e231-e236. DOI:10.1016/j.jaad.2018.11.036
Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. Jan 2021;35(1):50-61. DOI:10.1111/jdv.16677
Avcı C, Akın G, Akarsu S, Lebe B. Pyoderma gangrenosum and Behçet's-like disease induced by secukinumab: a paradoxical drug reaction. J Dermatolog Treat. Dec 2023;34(1):2235040. DOI:10.1080/09546634.2023.2235040
Clemente-Hernández B, Álvarez-Salafranca M, Muelas-Rives I, Ollero-Domenche L, Gracia-Cazaña T, Gilaberte Y. Multifocal pyoderma gangrenosum induced by secukinumab in a patient with hidradenitis suppurativa. Indian J Dermatol Venereol Leprol. Jul 25 2024:1-3. DOI:10.25259/ijdvl_329_2024
Orita A, Hoshina D, Hirosaki K. Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review. Clin Exp Dermatol. Jul 2022;47(7):1372-1374. DOI:10.1111/ced.15183
Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep. Aug 2020;6(8):731-733. DOI:10.1016/j.jdcr.2020.06.011
Wollina U, Schönlebe J, Fürll C. Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction. Dermatol Ther. Jan 2020;33(1):e13161. DOI:10.1111/dth.13161
Jin K, Matsuzaki Y, Akasaka E, Nakano H, Sawamura D. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol. Mar 2019;46(3):e108-e109. DOI:10.1111/1346-8138.14611
Benzaquen M, Monnier J, Beaussault Y, Rouby F, Berbis P. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab. Australas J Dermatol. Nov 2017;58(4):e270-e271. DOI:10.1111/ajd.12545
Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. Oct 2011;147(10):1203-5. DOI:10.1001/archdermatol.2011.168
Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. Jun 2017;18(3):355-372. DOI:10.1007/s40257-017-0251-7
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ece Erbağcı, Özge Sevil Karstarlı Bakay, Fatma Aslı Hapa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
